hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (FDA) to manufacture ibuprofen and famotidine tablets, 800 mg/26.6 mg. (USRLD: Duexis ...

Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multiple strengths. The ...

Zydus Lifesciences share price will remain in focus on March 6 after the company received final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Pimavanserin tablets in strength of 10 mg, Zydus Cadila said in a statement. Zydus Cadila ...